tradingkey.logo

Tivic Health Systems Inc

TIVC
1.890USD
0.000
收盘 12/24, 13:00美东报价延迟15分钟
3.14M总市值
亏损市盈率 TTM

Tivic Health Systems Inc

1.890
0.000

关于 Tivic Health Systems Inc 公司

Tivic Health Systems, Inc. is a diversified therapeutics company, with complementary bioelectronic and biologic product candidates in its clinical pipeline. It harnesses the power of the immune and autonomic nervous systems to fight disease and restore health. It takes a multi-pronged approach to treating diseases caused by immune dysregulation and dysautonomia. The complement of bioelectronic and biologic medicines allows it to target disorders and disease via both neural pathways and molecular approaches. Its commercial product, ClearUP, is clinically proven to treat sinus pain and pressure. ClearUP is available through online retailers and commercial distributors. It also has worldwide exclusive license rights to the late-stage Toll-like Receptor 5 (TLR5) agonist Entolimod for the treatment of acute radiation syndrome (ARS). In addition, it has an exclusive option to license five additional indications and clinical use cases for Entolimod and its derivative, Entalasta.

Tivic Health Systems Inc简介

公司代码TIVC
公司名称Tivic Health Systems Inc
上市日期Nov 11, 2021
CEOErnst (Jennifer)
员工数量7
证券类型Ordinary Share
年结日Nov 11
公司地址47685 Lakeview Blvd
城市FREMONT
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编94538
电话18882766888
网址https://tivichealth.com/
公司代码TIVC
上市日期Nov 11, 2021
CEOErnst (Jennifer)

Tivic Health Systems Inc公司高管

名称
名称/职务
职务
持股
持股变动
Ms. Jennifer Ernst
Ms. Jennifer Ernst
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
23.25K
+3192.78%
Ms. Lisa Wolf
Ms. Lisa Wolf
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Michael K. Handley
Mr. Michael K. Handley
Chief Operating Officer and President of Tivic Biopharma
Chief Operating Officer and President of Tivic Biopharma
--
--
Ms. Christina Valauri
Ms. Christina Valauri
Independent Director
Independent Director
--
--
Mr. Dean Zikria
Mr. Dean Zikria
Independent Director
Independent Director
--
--
Mr. Jim Hock
Mr. Jim Hock
Investor Relations
Investor Relations
--
--
Ms. Sheryle J Bolton
Ms. Sheryle J Bolton
Independent Chairman of the Board
Independent Chairman of the Board
--
--
名称
名称/职务
职务
持股
持股变动
Ms. Jennifer Ernst
Ms. Jennifer Ernst
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
23.25K
+3192.78%
Ms. Lisa Wolf
Ms. Lisa Wolf
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Michael K. Handley
Mr. Michael K. Handley
Chief Operating Officer and President of Tivic Biopharma
Chief Operating Officer and President of Tivic Biopharma
--
--
Ms. Christina Valauri
Ms. Christina Valauri
Independent Director
Independent Director
--
--
Mr. Dean Zikria
Mr. Dean Zikria
Independent Director
Independent Director
--
--
Mr. Jim Hock
Mr. Jim Hock
Investor Relations
Investor Relations
--
--

收入明细

由于公司未披露,未能获取相关数据
由于公司未披露,未能获取相关数据
业务
地区
由于公司未披露,未能获取相关数据

股东统计

更新时间: 12月24日 周三
更新时间: 12月24日 周三
持股股东
股东类型
持股股东
持股股东
占比
Avenue Capital Group
5.76%
Statera BioPharma, Inc
3.47%
DRW Securities, LLC
3.05%
Avenue Venture Opportunities Fund LP
2.84%
Marex Group plc
2.17%
其他
82.71%
持股股东
持股股东
占比
Avenue Capital Group
5.76%
Statera BioPharma, Inc
3.47%
DRW Securities, LLC
3.05%
Avenue Venture Opportunities Fund LP
2.84%
Marex Group plc
2.17%
其他
82.71%
股东类型
持股股东
占比
Corporation
6.30%
Investment Advisor/Hedge Fund
6.04%
Investment Advisor
5.38%
Individual Investor
1.37%
Research Firm
0.08%
其他
80.82%

机构持股

更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
22
44.96K
2.86%
+5.91K
2025Q2
32
112.57K
10.82%
+62.79K
2025Q1
32
1.24K
0.18%
-48.58K
2024Q4
34
288.82K
2.82%
-516.93K
2024Q3
32
301.13K
4.87%
-468.33K
2024Q2
32
639.36K
10.34%
+419.46K
2024Q1
34
88.08K
6.01%
-141.85K
2023Q4
34
75.33K
5.40%
-149.34K
2023Q3
33
160.42K
18.20%
+130.18K
2023Q2
33
60.32K
19.16%
+13.93K
查看更多

股东持股明细

名称
持股数
占比
持股变动
变动比例
公告日期
Statera BioPharma, Inc
61.20K
3.89%
+61.20K
--
May 14, 2025
Avenue Venture Opportunities Fund LP
50.13K
3.18%
+50.13K
--
May 14, 2025
Marex Group plc
39.28K
2.5%
+39.28K
--
Jun 30, 2025
Ernst (Jennifer)
23.25K
1.48%
+22.54K
+3192.78%
Sep 22, 2025
Geode Capital Management, L.L.C.
--
0%
-2.15K
-100.00%
Mar 31, 2025
UBS Financial Services, Inc.
5.65K
0.36%
+5.65K
--
Jun 30, 2025
查看更多

持股ETF

机构名称
占比
暂无数据

分红派息

近5年累计派现 0.00 美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据

拆合股

公告日期
类型
比率
Mar 05, 2025
Merger
17→1
Mar 05, 2025
Merger
17→1
Mar 05, 2025
Merger
17→1
Mar 05, 2025
Merger
17→1
Aug 22, 2023
Merger
100→1
Aug 22, 2023
Merger
100→1
公告日期
类型
比率
Mar 05, 2025
Merger
17→1
Mar 05, 2025
Merger
17→1
Mar 05, 2025
Merger
17→1
Mar 05, 2025
Merger
17→1
Aug 22, 2023
Merger
100→1
Aug 22, 2023
Merger
100→1
Aug 22, 2023
Merger
100→1
Aug 22, 2023
Merger
100→1

常见问题

Tivic Health Systems Inc的前五大股东是谁?

Tivic Health Systems Inc 的前五大股东如下:
Statera BioPharma, Inc持有股份:61.20K,占总股份比例:3.89%。
Avenue Venture Opportunities Fund LP持有股份:50.13K,占总股份比例:3.18%。
Marex Group plc持有股份:39.28K,占总股份比例:2.50%。
Ernst (Jennifer)持有股份:23.25K,占总股份比例:1.48%。
Geode Capital Management, L.L.C.持有股份:0.00,占总股份比例:0.00%。

Tivic Health Systems Inc的前三大股东类型是什么?

Tivic Health Systems Inc 的前三大股东类型分别是:
Avenue Capital Group
Statera BioPharma, Inc
DRW Securities, LLC

有多少机构持有Tivic Health Systems Inc(TIVC)的股份?

截至2025Q3,共有22家机构持有Tivic Health Systems Inc的股份,合计持有的股份价值约为44.96K,占公司总股份的2.86%。与2025Q2相比,机构持股有所增加,增幅为-7.96%。

哪个业务部门对Tivic Health Systems Inc的收入贡献最大?

在--,--业务部门对Tivic Health Systems Inc的收入贡献最大,创收--,占总收入的--%。
KeyAI